Jeevan Scientific Technology Limited Stock

Equities

JSTL6

INE237B01018

Biotechnology & Medical Research

Market Closed - Bombay S.E. 06:00:55 2024-05-23 am EDT 5-day change 1st Jan Change
47.89 INR +3.34% Intraday chart for Jeevan Scientific Technology Limited -0.08% -21.98%
Sales 2022 678M 8.14M Sales 2023 362M 4.34M Capitalization 746M 8.96M
Net income 2022 119M 1.43M Net income 2023 -30M -360K EV / Sales 2022 2.68 x
Net cash position 2022 172M 2.07M Net Debt 2023 32.61M 392K EV / Sales 2023 2.15 x
P/E ratio 2022
17.5 x
P/E ratio 2023
-24.4 x
Employees 250
Yield 2022
0.92%
Yield 2023
-
Free-Float 36.73%
More Fundamentals * Assessed data
Dynamic Chart
Jeevan Scientific Technology Limited Announces Executive Changes, Effective March 31, 2024 CI
US FDA Clears Jeevan Scientific Technology's Bioanalytical Plant in Hyderabad, India MT
Jeevan Scientific Technology Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jeevan Scientific Technology Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Jeevan Scientific Arm Ties Up with Aditri Pharm Sciences for Pharmaceutical Preparations MT
Jeevan Scientific Technology Limited Announces Cessation of Surapaneni Sree Rama Koteswara Rao as Independent Director CI
Jeevan Scientific Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Jeevan Scientific Technology Limited Announces Resignation of Rama Krishna Prasad Kakarala as Non- Executive Director CI
Jeevan Scientific Technology Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Jeevan Scientific Technology Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Jeevan Scientific Technology Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Nayas Laboratories Private Limited announced that it has received $20 million in funding from Jeevan Scientific Technology Limited CI
Jeevan Scientific Technology Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Jeevan Scientific Technology Limited Declares Dividend for the Financial Year Ended March 31, 2022 CI
Jeevan Scientific Technology Names New CFO MT
More news
1 day+3.34%
1 week-0.08%
Current month-8.78%
1 month-9.30%
3 months-14.33%
6 months-15.98%
Current year-21.98%
More quotes
1 week
45.02
Extreme 45.02
49.40
1 month
45.02
Extreme 45.02
55.08
Current year
42.16
Extreme 42.16
70.00
1 year
38.60
Extreme 38.6
70.94
3 years
38.60
Extreme 38.6
229.45
5 years
14.10
Extreme 14.1
229.45
10 years
12.15
Extreme 12.15
229.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 31 18-03-31
Director of Finance/CFO 34 20-11-01
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Compliance Officer - 17-04-09
Director/Board Member 47 09-01-30
Director/Board Member - 00-02-27
More insiders
Date Price Change Volume
24-05-23 47.89 +3.34% 11,392
24-05-22 46.34 -0.75% 7,808
24-05-21 46.69 -1.37% 24,248
24-05-18 47.34 -1.23% 1,832
24-05-17 47.93 -0.02% 11,269

Delayed Quote Bombay S.E., May 23, 2024 at 06:00 am EDT

More quotes
Jeevan Scientific Technology Limited is an India-based company, which provides technology-driven services and solutions to its clients across the globe. The Company’s service portfolio enables its clients to provide an integrated solution for the management of clinical data from its inception to completion. The Company offers a range of clinical trial services from Phase II to IV for pharmaceutical, biotechnology and medical device to bring new drugs and devices into global reach faster. It also provides its services to other areas, such as cosmetics and nutraceuticals. Its clinical trial services include medical writing, clinical trial management, clinical trial monitoring, drug safety management, clinical data management, biostatistics and statistical programming, and quality assurance. It offers comprehensive pharmacovigilance and safety monitoring services from early development support through post-approval initiatives.
More about the company